Naoki Kashihara

Naoki Kashihara

Auto-generated profile, based on publicly available information

Naoki Kashihara

Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
SKSeiji Kishi
Seiji Kishi
HNHajime Nagasu
Hajime Nagasu
KKKengo Kidokoro
Kengo Kidokoro
NKNaoki Kashihara
Naoki Kashihara

13 February 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YHYoshisuke Haruna
Yoshisuke Haruna
NKNaoki Kashihara
Naoki Kashihara
MSMinoru Satoh
Minoru Satoh
NTNaruya Tomita
Naruya Tomita
TNTamehachi Namikoshi
Tamehachi Namikoshi
YKYashpal S. Kanwar
Yashpal S. Kanwar
Klotho , an antiaging gene with restricted organ distribution, is mainly expressed in the kidney tubules; the mutant mice have shortened life span, arteriosclerosis, anemia, and osteoporesis, features common to patients with chronic renal failure. Conceivably, the reduction of the Klotho gene expression may contribute to the development of kidney failure; alternatively, its overexpression may lead to the amelioration of renal injury in an ICR-derived glomerulonephritis (ICGN) mouse model with subtle immune complex-mediated disease. To address this issue, four different strains of mice were generated by cross-breeding: ICGN mice without the Klotho transgene (ICGN), ICGN mice with the Klotho transgene (ICGN/klTG), wild-type mice with the Klotho transgene (klTG), and wild-type mice without the Klotho transgene (control). At 40 weeks old, the survival rate was ≈30% in ICGN mice, and ≈70% in the ICGN/klTG group. This improvement was associated with dramatic improvement in renal functions, morphological lesions, and cytochrome c oxidase activity but a reduction in β-galactosidase activity (a senescence-associated protein), mitochondrial DNA fragmentation, superoxide anion generation, lipid peroxidation, and Bax protein expression and apoptosis. Interestingly, improvement was seen in both the tubular and glomerular compartments of the kidney, although Klotho is exclusively confined to the tubules, suggesting that its gene product has a remarkable renoprotective effect by potentially serving as a circulating hormone while mitigating the mitochondrial oxidative stress.

8 July 2024 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
SKSeiji Kishi
Seiji Kishi
HKHiroyuki Kadoya
Hiroyuki Kadoya
NKNaoki Kashihara
Naoki Kashihara

1 January 2007 in Hypertension Research
Verified
Journal Article
Closed access
TNTamehachi Namikoshi
Tamehachi Namikoshi
NTNaruya Tomita
Naruya Tomita
SFSohachi Fujimoto
Sohachi Fujimoto
YHYoshisuke Haruna
Yoshisuke Haruna
MOMasahito Ohzeki
Masahito Ohzeki
NKNaoki Kashihara
Naoki Kashihara
Hypertension Research, official publication of the Japanese Society of Hypertension, publishes papers reporting original clinical and experimental research in the field of hypertension and related cardiovascular diseases.

17 July 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
HHHiddo Heerspink
Hiddo Heerspink
VPVlado Perkovic
Vlado Perkovic
KTKatherine R. Tuttle
Katherine R. Tuttle
PPPablo E. Pergola
Pablo E. Pergola
KMKenneth W. Mahaffey
Kenneth W. Mahaffey
GCGlenn M. Chertow
Glenn M. Chertow
Key Points: In a randomized, placebo-controlled, phase 2b study, we compared the effects of selonsertib with placebo on eGFR decline in people with type 2 diabetes and CKD. Patients taking selonsertib had slower eGFR decline but were more likely to reach a composite kidney outcome and report AKI. A larger trial with longer-term follow-up would more precisely assess the relative benefits and risks of selonsertib in this setting. Background: Selonsertib is an apoptosis signal–regulating kinase 1 inhibitor that reduces inflammation, fibrosis, and apoptosis. The MOSAIC study evaluated whether selonsertib attenuated kidney function decline in patients with diabetic kidney disease. Methods: We conducted a phase 2b study in adults with type 2 diabetes and eGFR 20 to <60 ml/min per 1.73 m2 with urine albumin-creatinine ratio 150–5000 mg/g on maximum tolerated dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. To account for an acute selonsertib-related decrease in serum creatinine–based eGFR (eGFRcr), patients entered a 4-week selonsertib run-in period to establish treatment-specific baseline eGFRcr. Patients were randomized 1:1 to selonsertib 18 mg or matching placebo once daily. We followed all participants up until the last randomized participant completed 48 weeks of follow-up. The primary efficacy outcome was the difference in eGFRcr slopes from treatment-specific baselines to week 84, evaluated at a prespecified two-sided P = 0.30. We also evaluated kidney clinical events (eGFRcr ≥40% decline from pre–run-in baseline, kidney failure, or death due to kidney disease) and adverse events. Results: In total, 310 patients were randomized (selonsertib n=154, placebo n=156; 68% male, mean age 65 years, mean baseline eGFRcr 35 ml/min per 1.73 m2). Mean difference between selonsertib and placebo eGFRcr slopes at week 84 was 1.20 ml/min per 1.73 m2 per year (95% confidence interval, −0.41 to 2.81; P = 0.14). Kidney clinical events occurred in 17% (26/154) of patients randomized to selonsertib and 12% (19/156) of those randomized to placebo (difference 4.7%; 95% confidence interval, −6.3% to 15.9%). The most common investigator-reported adverse event was AKI (selonsertib 11.0/100 and placebo 5.9/100 patient-years). Conclusions: Selonsertib attenuated the decline in eGFRcr over up to 84 weeks; however, it resulted in a numerically higher number of patients reaching a kidney clinical event and a numerically higher rate of investigator-reported AKI. Clinical Trial registry name and registration number: Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease (MOSAIC), NCT04026165.

1 January 2020 in Current Opinion in Nephrology and Hypertension
Verified
Journal Article
Closed access
NKNaoki Kashihara
Naoki Kashihara
KKKengo Kidokoro
Kengo Kidokoro
EKEiichiro Kanda
Eiichiro Kanda
Emerging data have demonstrated that sodium-glucose cotransporter-2 (SGLT2) inhibitors prevent cardiovascular events, especially heart failure-associated endpoints. Cardiovascular outcome trials have also suggested their renoprotective effects. One large clinical trial investigated renal primary endpoints and demonstrated that SGLT2 inhibitors slowed the progression of diabetic kidney disease (DKD). This review summarizes clinical trial data on renal outcomes and discusses potential underlying mechanisms. The EMPA-REG, CANVAS, and DECLARE-TIMI 58 studies revealed that SGLT2 inhibitors reduce the risk of cardiovascular events and concomitantly suggested that these drugs slow the progression of kidney disease in type 2 diabetes. The CREDENCE trial on patients with high-risk type 2 diabetes and chronic kidney disease demonstrated that canagliflozin treatment reduced the relative risk of a composite outcome, including end-stage kidney disease, serum creatinine doubling, and renal/cardiovascular death, by 30% in these patients. Animal experiments revealed that oxidative stress, inflammation, fibrosis, and tubuloglomerular feedback are underlying renoprotective mechanisms behind SGLT2 inhibitors. Recent clinical trials have established the renoprotective effects of SGLT2 inhibitors. Further investigations on mechanisms of these renoprotective effects will provide deeper insights and understanding of pathogenetic properties of DKD.